Common Stock, par value $0.01 per share
- Symbol
- IRIX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
IRIDEX Corporation
IRIXNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 18, 2026, IRIDEX Corporation issued a press release discussing its financial results for its second fiscal quarter ended July 4, 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.…
Press release in this filing
Iridex Reports Second Quarter 2026 Financial Results →Company context
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Current securities
Recent company filings
- 4 filingSep 16, 2026
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingSep 2, 2026
- 10-Q filingAug 18, 2026
- Submission of Matters to a Vote of Security Holders · Regulation FD DisclosureJul 16, 2026
- SCHEDULE 13D/A - filed by Novel Inspiration International Co., Ltd. regarding IRIDEX CORPJul 13, 2026
Registered securities in this filing
IRIDEX CORPORATION · 8-K · Filed 2026-08-18
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On August 18, 2026, IRIDEX Corporation issued a press release discussing its financial results for its second fiscal quarter ended July 4, 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 2 irix-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Iridex Reports Second Quarter 2026 Financial Results MOUNTAIN VIEW, Calif., August 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 4, 2026. Second Quarter 2026 Financial Highlights • Generated total revenue of $12.6 million, compared to $13.6 million in the prior year period • Cyclo G6® product family revenue was $3.9 million, representing growth of 19% year-over-year compared to $3.3 million in the prior year period o Sold 17,700 Cyclo G6 probes compared to 13,100 in the prior year period o Sold 18 Cyclo G6 Glaucoma Laser Systems compared to 35 in the prior year period • Retina product revenue was $6.5 million compared to $8.0 million in the prior year period • Operating cash flow positive second quarter 2026 “Our second quarter results were highlighted by the continued momentum in our glaucoma business and operating positive cash flows,” said Patrick Mercer, Pre…
Open exhibit ↗